154 related articles for article (PubMed ID: 26088718)
1. Common Models, Different Approaches.
Gagne JJ
Drug Saf; 2015 Aug; 38(8):683-6. PubMed ID: 26088718
[No Abstract] [Full Text] [Related]
2. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
[TBL] [Abstract][Full Text] [Related]
3. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
[TBL] [Abstract][Full Text] [Related]
4. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?
Coloma PM; Trifirò G; Patadia V; Sturkenboom M
Drug Saf; 2013 Mar; 36(3):183-97. PubMed ID: 23377696
[TBL] [Abstract][Full Text] [Related]
5. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
Lin KJ; Schneeweiss S
Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
[TBL] [Abstract][Full Text] [Related]
6. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.
de Bie S; Coloma PM; Ferrajolo C; Verhamme KM; Trifirò G; Schuemie MJ; Straus SM; Gini R; Herings R; Mazzaglia G; Picelli G; Ghirardi A; Pedersen L; Stricker BH; van der Lei J; Sturkenboom MC;
Br J Clin Pharmacol; 2015 Aug; 80(2):304-14. PubMed ID: 25683723
[TBL] [Abstract][Full Text] [Related]
7. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'.
Ryan PB; Madigan D; Stang PE; Marc Overhage J; Racoosin JA; Hartzema AG
Stat Med; 2013 Mar; 32(6):1075-7. PubMed ID: 23413215
[No Abstract] [Full Text] [Related]
8. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
Moore TJ; Furberg CD
Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
[TBL] [Abstract][Full Text] [Related]
9. Identifying Data Elements to Measure Frailty in a Dutch Nationwide Electronic Medical Record Database for Use in Postmarketing Safety Evaluation: An Exploratory Study.
Sultana J; Leal I; de Wilde M; de Ridder M; van der Lei J; Sturkenboom M; Trifiro' G
Drug Saf; 2019 Jun; 42(6):713-719. PubMed ID: 30617499
[TBL] [Abstract][Full Text] [Related]
10. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
11. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
Gagne JJ; Schneeweiss S
Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
[No Abstract] [Full Text] [Related]
12. Attractive tools for systematic case accumulation.
Oshima Y; Tojo A
Int J Hematol; 2011 Oct; 94(4):413-414. PubMed ID: 21877112
[No Abstract] [Full Text] [Related]
13. Drug-safety pilot makes the grade.
Ledford H
Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
[No Abstract] [Full Text] [Related]
14. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
Pacurariu A; Plueschke K; McGettigan P; Morales DR; Slattery J; Vogl D; Goedecke T; Kurz X; Cave A
BMJ Open; 2018 Sep; 8(9):e023090. PubMed ID: 30185579
[TBL] [Abstract][Full Text] [Related]
15. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
[No Abstract] [Full Text] [Related]
16. [Is it possible to do pharmaco-epidemiological research using electronic databanks in the Swiss health care system?].
Meier ChR
Praxis (Bern 1994); 2003 May; 92(21):997-1000. PubMed ID: 12806695
[No Abstract] [Full Text] [Related]
17. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association.
Gagne JJ; Han X; Hennessy S; Leonard CE; Chrischilles EA; Carnahan RM; Wang SV; Fuller C; Iyer A; Katcoff H; Woodworth TS; Archdeacon P; Meyer TE; Schneeweiss S; Toh S
Clin Pharmacol Ther; 2016 Nov; 100(5):558-564. PubMed ID: 27416001
[TBL] [Abstract][Full Text] [Related]
18. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
[TBL] [Abstract][Full Text] [Related]
19. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
Kuehn BM
JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
[No Abstract] [Full Text] [Related]
20. Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Real-World Data From Electronic Health Records.
Choi L; Beck C; McNeer E; Weeks HL; Williams ML; James NT; Niu X; Abou-Khalil BW; Birdwell KA; Roden DM; Stein CM; Bejan CA; Denny JC; Van Driest SL
Clin Pharmacol Ther; 2020 Apr; 107(4):934-943. PubMed ID: 31957870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
